Russian scientists have successfully developed an innovative drug for the treatment of ankylosing spondylitis, which was previously practically incurable, said the rector of the Russian National Research Medical University named after NI Pirogov, academician of the Academy of Sciences of Russia, Sergei Lukyanov, RIA Novosti reported on November 27. .
Sergei Lukyanov, who has personal experience in the fight against this disease, together with a team of scientists, developed a new drug, BCD-180.
Ankylosing spondylitis, also known as ankylosing spondylitis, is characterized by ossification of the spine and joints and was previously considered incurable. In severe cases, the person is practically unable to move. The exact causes are unknown.
The drug itself is a cytotoxic antibody that can recognize and destroy specific cells of the immune system responsible for the development of the disease. Its goal is to destroy autoaggressive T lymphocytes, which are considered the cause of the disease.
“People usually get sick in their late teens or adults under 45 years old. In the early stages, pain in the lower back, especially in the morning. Then, stiffness in the spine, which, as a rule, decreases with movement.””, clarifies the scientist.
Lukyanov personally faced ankylosing spondylitis and lived with this disease for more than 25 years. This experience gave him a unique understanding of how the disease affects a person’s life and what treatment approaches may be most effective.
While working on the drug, Lukyanov became one of the first testers of this drug. Which, of course, was very risky, but in the end it allowed him to personally evaluate the effectiveness and safety of the drug.
The creation of the drug has opened new horizons in the treatment of autoimmune diseases, minimizing the side effects of traditional immunosuppressive therapy.
Bekhterev’s disease, described at the end of the 19th century by the Russian scientist Vladimir Bekhterev, remained difficult to cure for a long time. Previous treatments, including anticytokine therapy, did not solve the problem at the root. The new approach developed by Lukyanov and his team focuses on precisely targeting and killing disease-causing cells. This discovery was published in Nature Medicine and received approval for late-stage clinical trials, paving the way for the drug to be introduced into medical practice.
Source: Rossa Primavera
I am Michael Melvin, an experienced news writer with a passion for uncovering stories and bringing them to the public. I have been working in the news industry for over five years now, and my work has been published on multiple websites. As an author at 24 News Reporters, I cover world section of current events stories that are both informative and captivating to read.